RXi Pharmaceuticals Corp. has named Dr. Rolf Kiessling, professor in experimental oncology at Karolinska Institutet, to its Scientific Advisory Board.
"This is an exciting time for RXi Pharmaceuticals as they expand development efforts using their proprietary self-delivering RNAi technology in the field of cell-based immunotherapy," Kiessling, who also is senior chief physician of Radiumhemmet at Karolinska Hospital, said in a news release. "I welcome the opportunity to work with the accomplished team of advisors at RXi and look forward to being a part of their mission to develop innovative therapeutics to improve patients' lives."
With vast scientific expertise in the field of experimental and clinical immunology, Kiessling is also accredited with the discovery for Natural Killer cells (NK cells) in the mid-1970s and has published over 250 articles in peer-reviewed journals, the news release said.
"We are honored to have Dr. Kiessling join our Scientific Advisory Board," Dr. Pamela Pavco, chief development officer of RXi Pharmaceuticals, said in the release. "He brings a wealth of invaluable insight and guidance as we pursue the development of cell-based immuno-oncology therapeutics, in addition to our dermatology and ophthalmology programs."
RXi is a clinical-stage RNAi company that develops innovative therapeutics focusing on significant unmet medical needs.